



412852

Trial_Count

2.4bn

Total Enrollments

0.70

Trial Withdrawal Rate

101 Therapeutics

1/31/1900



1/1/2100



Clinical Trial Sponsors

name

01 Expert Systems, LLC

1 Million 4 Anna Foundation

100 medical centers in the China PE-DVT network

101 Therapeutics

105 Hospital of Chinese People's Liberation Army

108 Military Central Hospital, Hanoi, Viet Nam

10xBio, LLC

Institute Conducting Study

name

- Andalusian Public Foundation for Health Research Management in Seville (FISEVI)

ATTIKON University Hospital


ATTIKON University Hospital

City Polyclinic #25 of the Nevsky District of SPB Prospekt Solidarnosti, 1, bldg 1, litera A

- CRC Centro Ricerche Cliniche di Verona

- Department of Paediatric Medicine, CF Center, A. Meyer Children's Hospital

Overall Trial Status by facilities



Overall Status by Country using studies table



Source of Clinical Trial Study

source	Total facilities of source
National Cancer Institute (NCI)	146508
AstraZeneca	133579
Pfizer	105909
Novartis	98233
Hoffmann-La Roche	85277
GlaxoSmithKline	81637
Total	2962474

Source for Clinical Trial
National Cancer Institute (NCI)

Sponsor Of Clinical Trial Study

Name of Sponsor
[Redacted]
01 Expert Systems, LLC
1 Million 4 Anna Foundation
100 medical centers in the China PE-DVT network
101 Therapeutics
105 Hospital of Chinese People's Liberation Army
108 Military Central Hospital, Hanoi, Viet Nam

Facility where Research Conducted

name
首都医科大学附属北京安贞医院
辛玉霞
路平
苏州大学
第四军医大学
石芸
王芳
王振宇

Enrollment representative for Clinical Trial

name	email
((Wei Li[Author])	lwqfsh@126.com
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Informat	dsclinicaltrial@daiichi
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information	dsclinicaltrial@daiichi
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information	dsclinicaltrial@daiichi
(Asia sites)Toray Contact for Clinical Trial Information	npdd-clinical.toray.mk

Scientific Information Representative for Clinical Trial

name	em
: Bristol-Myers Squibb Study Director	Clini
4968 Clinical Trial Leader	med
A study to assess the safety, tolerability, pharmacokinetics & dynamics of AZD5718 in healthy male	clini
Abhijit Barve, Head of Global Clinical Research	abhi
Adam Mendizabal, PhD	ame





Trial Details

Trial Description

source	brief_title
National Cancer Institute (NCI)	10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)	17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)	17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)	17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
National Cancer Institute (NCI)	17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
National Cancer Institute (NCI)	17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
National Cancer Institute (NCI)	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
National Cancer Institute (NCI)	17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
National Cancer Institute (NCI)	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
National Cancer Institute (NCI)	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Operational Status

study_type	phase	Condition Name	overall_status
Interventional	Phase 1	Accelerated Phase Chronic Myelogenous Leukemia	Completed
Interventional	Phase 1	Accelerated Phase Chronic Myelogenous Leukemia	Terminated
Interventional	Phase 1/Phase 2	Accelerated Phase Chronic Myelogenous Leukemia	Completed

Study Document URLs

id_link
https://reporter.nih.gov/quickSearch/1R01CA134620
https://reporter.nih.gov/quickSearch/K23CA178183
https://reporter.nih.gov/quickSearch/K23CA190849
https://reporter.nih.gov/quickSearch/K24CA139052
https://reporter.nih.gov/quickSearch/K24CA201524
https://reporter.nih.gov/quickSearch/N01CM00032

SAP Document URLs

url
https://ClinicalTrials.gov/ProvidedDocs/00/NCT02446600/Prot_SAP_000.pdf
https://ClinicalTrials.gov/ProvidedDocs/00/NCT02498600/Prot_SAP_000.pdf
https://ClinicalTrials.gov/ProvidedDocs/01/NCT01514201/Prot_SAP_000.pdf
https://ClinicalTrials.gov/ProvidedDocs/01/NCT02417701/Prot_SAP_000.pdf
https://ClinicalTrials.gov/ProvidedDocs/01/NCT01430001/Prot_SAP_000.pdf

Trial Protocol URLs


url
http://jnm.snmjournals.org/content/early/2015/09/09/jnumed.115.160663.long
http://nctn-data-archive.nci.nih.gov/
http://www.cancer.gov/
http://www.cancer.gov/nlst
http://www.fhcrc.org
http://www.mdanderson.org
http://www.mskcc.org






Country Demographics


Select all	Afghanistan	Albania	American Samoa	Angola	Antigua and Barbuda	Armenia	Australia	Azerbaijan	Bahrain	Barbados	Belgium
	Aland Islands	Algeria	Andorra	Antarctica	Argentina	Aruba	Austria	Bahamas	Bangladesh	Belarus	Belize




Trial Count In USA




Trial Count In Pakistan



USA Trial Count by Region



Pakistan Trial Count by Region




Year	Sum of subjects_at_risk	Sum of number_of_facilities	number_of_facilities_measure	Quick Measure Count of sorted_country_names(group_by) average per number_of_facilities
+	1181608	134875	134875	20,129.00
+ 1900		6	6	2.00
+ 1972		1	1	1.00
+ 1979		1	1	1.00
+ 1988		3	3	3.00
+ 1989		31	31	7.00
+ 1990	74	181	181	30.00
+ 1991	468	82	82	21.00
+ 1992		228	228	34.00
+ 1993	1032	309	309	46.00
+ 1994	1695	481	481	43.00
Total	63733688	2962790	2962790	660,850.00

overall_status	Total_Facilities
Completed	1752140
Recruiting	411646
Active, not recruiting	353212
Terminated	252712
Unknown status	119109
Not yet recruiting	21195
Withdrawn	18871
Enrolling by invitation	13341
Suspended	11893
No longer available	3805
Approved for marketing	3659
Available	1192
Temporarily not available	15
Total	2962790

country	Count_of_trials_by_country
Zimbabwe	184
Zambia	282
Yemen	4
Virgin Islands (U.S.)	7
Vietnam	828
Venezuela	186
Vanuatu	2
Uzbekistan	44
Uruguay	86
United States Minor Outlying Islands	2
United States	168439
United Kingdom	24463
United Arab Emirates	413
Ukraine	2466
Uganda	809
Turkey	13082
Total	425653

Overall Status by Country using studies table by overall_status



country	Active, not recruiting	Available	Completed	Enrolling by invitation	Not yet recruiting	Recruiting	Suspended	Terminated	Withdrawn	Total
Pakistan	2082	2		1	16	726				2818
United States	140682	1117	84	713	49	2218	27415	268	331	802
Total	142698	1119	84	713	50	2232	28129	268	331	802


sorted_country_names(group_by)	Count_of_Trials_(including_recently_added)in_Pakistan
Pakistan	2851
Total	2851

sorted_country_names(group_by)	Count_of_Trials_(Including_recently_added)in_USA
United States	173174
Total	173174

country	Active, not recruiting	Available	Completed	Enrolling by invitation	Not yet
Pakistan	2624	2		1	
United States	8730	738	3595		
Total	2624	8732	738	3595	1


country	Trial_Count	%_of_all_trials
United States	168439	39.57
France	35218	8.27
China	33381	7.84
Canada	27949	6.57
Germany	24798	5.83
United Kingdom	24463	5.75
Spain	19997	4.70
Italy	19702	4.63
Korea, Republic of	14766	3.47
Turkey	13082	3.07
Total	425667	100.00

statuscount_by_facilities_measu
re2 by status



nct_id	Sum of enrollment	Total_Participant_Enrollment	Drop_Withdrawl_Count_Per_Trial_0	Withdrawl_Rate_Per_Trial
NCT00000105	112	112		
NCT00000113	469	469		
NCT00000116	221	221		
NCT00000125	1636	1636		
NCT00000134	279	279		
Total	2498760372	2498760372	17053106	0.68

nct_id	Sum of count	Drop_Withdrawl_Count_Per_Trial_0
NCT05993299	6	6
NCT05940077	1	1
NCT05896761	6	6
NCT05889039	6	6
NCT05867342	6	6
NCT05700400	2	2
Total	17053106	17053106



country	Active, not recruiting	Available	Completed	Enrolling by invitation	Not yet recruiting	Recruiting	Suspended	Terminated	Withdrawn	Total	
United States	8730	738	3595			146442	9847	1078	3309	173739	
Pakistan	2624	2		1	19	828				3474	
Total	2624	8732	738	3595	1	19	147270	9847	1078	3309	177213